ArticleTranslational lung cancer research2023

Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced

Makoto Nishio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.